You are here: Industry Insights > AstraZeneca

News List

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
Updates for the Janssen and AstraZeneca Vaccines Cross-contamination Lin Zhang
July 13, 2021
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes COVID-19 pandemic has spread to over 220 countries and territories around the world as of July 2021.
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care B3C newswire
November 06, 2023
SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK).
SeraNovo and AstraZeneca to Collaborate on Research Projects PharmaSources
May 16, 2023
SeraNovo is pleased to announce the closing of a multi-compound deal with AstraZeneca.SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi-compound deal with AstraZeneca.
AstraZeneca revenues soar with nearly $4bn in Covid-19 vaccine sales Pharmaceutical-Technology
February 11, 2022
The drugmaker, which is just beginning to profit from its Covid-19 vaccine, has recorded $37.4bn in revenue.
AstraZeneca reports 41% growth in FY 2021 total revenue Pharmaceutical-Technology
February 11, 2022
Total revenue for the Covid-19 sector was recorded at $4.11bn in FY 2021.
ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology b3cnewswire
February 11, 2022
ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
AstraZeneca-Daiichi Sankyo’s breast cancer therapy gets FDA priority review Pharmaceutical-Technology
January 19, 2022
The sBLA is based on results from the international, open-label Phase III DESTINY-Breast03 trial of Enhertu.
New AstraZeneca treatment for rare cancer reduces risk of death pharmatimes
January 19, 2022
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
BenevolentAI and AstraZeneca expand drug discovery partnership Pharmaceutical-Technology
January 17, 2022
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.